Literature DB >> 12408489

Biological half-life of iodine in adults with intact thyroid function and in athyreotic persons.

G H Kramer1, B M Hauck, M J Chamberlain.   

Abstract

A joint project between the Human Monitoring Laboratory (HML) and the Ottawa Hospital has measured the retention of 131I in patients who have received the radioiodine diagnostically. Thirty-nine subjects with intact thyroid glands and nine athyreotic subjects were measured in the HML's whole-body/thyroid counter to determine the retention of 131I following its medical administration. The average biological half-life of 131I in 26 euthyroid subjects was found to be 66.1+/-6.3 days which may he statistically significantly lower than the ICRP recommended value of 80 days. Nine hyperthyroid patients had a mean biological half-life of 38.2+/-8.6 days and in three hypothyroid patients the corresponding value was 29.3+/-8.8 days. Thyroid 131I uptake was measured in a conventional clinical fashion at the Ottawa Hospital Civic campus 24 h after oral administration of the radioiodine using a collimated thick sodium iodide detector placed over the neck anteriorly. Measured values were 10.144+/-0.009, 0.314+/-0.035 and 0.045+/-0.010 of the administered dose in euthyroid, hyperthyroid and hypothyroid patients respectively. The euthyroid range at the hospital is 0.06 - 0.22. Uptake was significantly lower for the euthyroid group than the ICRP value of 0.3. The radioiodine retention in athyreotic subjects followed a two compartment model with biological half-lives of 1.0+/-1.2 days and 18.4+/-1.1 days.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12408489     DOI: 10.1093/oxfordjournals.rpd.a006081

Source DB:  PubMed          Journal:  Radiat Prot Dosimetry        ISSN: 0144-8420            Impact factor:   0.972


  1 in total

1.  Determination of effective half-life of 131I in patients with differentiated thyroid carcinoma: comparison of cystatin C and creatinine-based estimation of renal function.

Authors:  Martin Freesmeyer; Falk Gühne; Christian Kühnel; Thomas Opfermann; Thomas Winkens; Anke Werner
Journal:  Endocrine       Date:  2018-11-01       Impact factor: 3.633

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.